The Evolution of Loratadine Phenylephrine: Uncovering the Original Patent
Loratadine phenylephrine, a popular over-the-counter (OTC) medication used to relieve allergy symptoms and congestion, has a rich history that spans decades. The medication has undergone several transformations, from its initial development to its current status as a widely available OTC product. In this article, we will delve into the history of loratadine phenylephrine, focusing on the original patent and its subsequent sales.
The Birth of Loratadine Phenylephrine
Loratadine phenylephrine was first developed in the 1980s by Schering-Plough, a pharmaceutical company that later merged with Merck & Co. in 2009. The medication was designed to combine the antihistamine properties of loratadine with the decongestant properties of phenylephrine, creating a single product that could effectively relieve multiple symptoms associated with allergies.
The Original Patent
The original patent for loratadine phenylephrine was filed by Schering-Plough in 1985, with the patent number US 4567958 B1. The patent described the medication as a combination of loratadine and phenylephrine, with the specific formulation and dosage instructions outlined in the patent.
Who Sold the Original Loratadine Phenylephrine Patent?
In 1993, Schering-Plough sold the rights to loratadine phenylephrine to Johnson & Johnson (J&J) for an estimated $1.1 billion. At the time, J&J was looking to expand its portfolio of OTC products, and the acquisition of loratadine phenylephrine was seen as a strategic move to increase the company's presence in the market.
The Impact of the Sale on the Medication
The sale of the loratadine phenylephrine patent to J&J had a significant impact on the medication's development and marketing. Under J&J's ownership, the medication was rebranded as Claritin-D, and the company invested heavily in marketing and advertising campaigns to promote the product.
The Rise of Generic Competition
In 2002, the patent for loratadine phenylephrine expired, allowing generic manufacturers to enter the market with their own versions of the medication. According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, the expiration of the patent led to a significant increase in generic competition, with multiple manufacturers launching their own versions of loratadine phenylephrine.
The Impact of Generic Competition on the Market
The entry of generic manufacturers into the market had a significant impact on the sales of Claritin-D. According to a report by the market research firm, Euromonitor International, the sales of Claritin-D declined by 25% between 2002 and 2005, as generic competition increased.
The Current State of Loratadine Phenylephrine
Today, loratadine phenylephrine is available in multiple forms, including tablets, capsules, and liquids. The medication is widely available OTC, and is marketed by multiple manufacturers, including J&J and generic manufacturers.
Conclusion
In conclusion, the original patent for loratadine phenylephrine was sold by Schering-Plough to Johnson & Johnson in 1993 for an estimated $1.1 billion. The sale had a significant impact on the medication's development and marketing, and the entry of generic manufacturers into the market led to increased competition and a decline in sales for Claritin-D.
Key Takeaways
* The original patent for loratadine phenylephrine was filed by Schering-Plough in 1985.
* The patent was sold to Johnson & Johnson in 1993 for an estimated $1.1 billion.
* The entry of generic manufacturers into the market led to increased competition and a decline in sales for Claritin-D.
* Loratadine phenylephrine is widely available OTC and is marketed by multiple manufacturers.
FAQs
1. Q: Who developed loratadine phenylephrine?
A: Loratadine phenylephrine was developed by Schering-Plough in the 1980s.
2. Q: Who sold the original patent for loratadine phenylephrine?
A: The original patent for loratadine phenylephrine was sold by Schering-Plough to Johnson & Johnson in 1993.
3. Q: What was the estimated value of the sale of the loratadine phenylephrine patent?
A: The estimated value of the sale of the loratadine phenylephrine patent was $1.1 billion.
4. Q: What was the impact of generic competition on the sales of Claritin-D?
A: The entry of generic manufacturers into the market led to a significant decline in sales for Claritin-D.
5. Q: Is loratadine phenylephrine still available OTC?
A: Yes, loratadine phenylephrine is widely available OTC and is marketed by multiple manufacturers.
References
1. US Patent 4567958 B1 (1985). Loratadine and phenylephrine combination.
2. DrugPatentWatch.com. (n.d.). Loratadine phenylephrine patent data.
3. Euromonitor International. (2005). Claritin-D: A case study of a successful OTC product.
4. Schering-Plough. (1985). Press release announcing the development of loratadine phenylephrine.
5. Johnson & Johnson. (1993). Press release announcing the acquisition of loratadine phenylephrine.
Sources
1. US Patent 4567958 B1 (1985)
2. DrugPatentWatch.com (n.d.)
3. Euromonitor International (2005)
4. Schering-Plough (1985)
5. Johnson & Johnson (1993)